| Computational framework for prioritizing candidate compounds overcoming the resistance of pancancer immunotherapy |
| 論文作者 |
Feng, FYM; He, T; Lin, P; Hu, JW; Shen, BH; Tang, ZX; Zhou, J; Fan, J; Hu, B; Li, H |
| 期刊/會(huì)議名稱 |
CELL REPORTS MEDICINE |
| 論文年度 |
2025 |
| 論文類別 |
|
| 摘要 |
Combination therapy has emerged as an effective approach to overcome resistance to immunotherapy. However, only a small number of drugs have been identified with synergistic effects with immunotherapy. Here, we develop a computational framework (IGeS-BS) to recommend compounds that potentially overcome resistance to immunotherapy. A meta-analysis of approximately 1,000 transcriptomes from immunotherapy patients revealed 33 tumor microenvironment (TME) signatures that can robustly and accurately estimate immunotherapy responses. An immuno-boosting landscape for more than 10,000 compounds and 13 cancer types was subsequently generated on The Cancer Genome Atlas (TCGA) and The Library of Integrated Network-Based Cellular Signatures (LINCS) datasets. Furthermore, the immuno-boosting effects of several high-scoring compounds were evaluated by in vitro and in vivo experiments in hepatocellular carcinoma and other cancer types. The results showed that the two best compounds (SB-366791 and CGP-60474) significantly alleviate the resistance of hepatocellular carcinoma to anti-PD1 therapy by activating immune cells. Collectively, our research provides an efficient framework for discovering compounds that enhance immunotherapy responses. |
| 卷 |
6 |
| 影響因子 |
10.6 |
官方微信
